NEW YORK (GenomeWeb News – Sequenom today reported preliminary full-year revenue of $162 million, an increase of 81 percent over the prior year but shy of consensus analyst estimates of $164.4 million.

Alongside its preliminary financial results, the company said that it is expanding its noninvasive prenatal testing menu by developing a "low cost test on an alternative platform" that it plans to launch by the end of the year. Sequenom's MaterniT21 Plus prenatal trisomy test currently runs on the Illumina sequencing platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.